

Joaquin Cabezas

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7187139/joaquin-cabezas-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

628
citations

15
h-index

22
g-index

66
ext. papers

969
ext. citations

5.4
avg. IF

3.71
L-index

#	Paper	IF	Citations
59	Management of Alcohol-Related Liver Disease and Its Complications.. <i>Clinical Drug Investigation</i> , 2022 , 1	3.2	0
58	Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFN γ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. <i>Viruses</i> , 2021 , 13,	6.2	1
57	Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 391-400	18.8	10
56	Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. <i>Scientific Reports</i> , 2021 , 11, 9819	4.9	1
55	High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. <i>United European Gastroenterology Journal</i> , 2021 , 9, 892-902	5.3	3
54	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
53	SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. <i>Journal of Hepatology</i> , 2021 , 74, 966-967	13.4	7
52	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021 , 74, 801-810	13.4	12
51	Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting. <i>International Journal of Drug Policy</i> , 2021 , 88, 103031	5.5	6
50	Telemedicine, time to change the paradigm of hepatitis C management: improve access and reduce costs In reference to: Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience, by PÉrez Hernández et al. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021 , 113, 623-624	0.9	1
49	Serum transferrin as a biomarker of hepatocyte nuclear factor 4 alpha activity and hepatocyte function in liver diseases. <i>BMC Medicine</i> , 2021 , 19, 39	11.4	2
48	HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?. <i>Journal of Hepatology</i> , 2021 , 75, 486-487	13.4	2
47	Anti-epileptic drugs and hepatitis C therapy: Real-world experience. <i>Journal of Hepatology</i> , 2021 , 75, 984-985	13.4	0
46	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
45	Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 1261-1265	3.4	0
44	Serum Transferrin Is an Independent Predictor of Mortality in Severe Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2020 , 115, 398-405	0.7	16
43	Strategy for the Elimination of Hepatitis C in Cantabria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 565-570	0.9	2

42	Principles for implementing a population screening strategy for hepatitis C in Spain. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020 , 112, 64-70	0.9	2
41	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020 , 174, 104694	10.8	20
40	Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 360-370	3.4	19
39	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3349-3358	5.1	7
38	Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. <i>Scientific Reports</i> , 2020 , 10, 15558	4.9	5
37	Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done. <i>Annals of Hepatology</i> , 2019 , 18, 236-239	3.1	1
36	MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	7
35	HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?. <i>Current Hepatology Reports</i> , 2019 , 18, 259-267	1	2
34	LOXL2-A New Target in Antifibrogenic Therapy?. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	31
33	Management of haemostatic alterations and associated disorders in cirrhosis in Spain: A national survey. <i>Digestive and Liver Disease</i> , 2019 , 51, 95-103	3.3	8
32	Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3
31	Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis. <i>Nature Communications</i> , 2019 , 10, 3126	17.4	46
30	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019 , 70, e493-e494	13.4	4
29	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 657-676	0.9	3
28	Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. <i>Cells</i> , 2019 , 8,	7.9	7
27	Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 657-676	0.1	1
26	Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort. <i>Liver International</i> , 2019 , 39, 90-97	7.9	4
25	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 54-64.e1	6.9	31

24	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 α Transactivation in Steatohepatitis. <i>Cell Metabolism</i> , 2018 , 27, 339-350.e3	24.6	34
23	TLR7-let-7 Signaling Contributes to Ethanol-Induced Hepatic Inflammatory Response in Mice and in Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2018 , 42, 2107-2122	3.7	14
22	Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. <i>World Journal of Clinical Cases</i> , 2018 , 6, 611-623	1.6	2
21	A Validated Score Predicts Acute Kidney Injury and Survival in Patients With Alcoholic Hepatitis. <i>Liver Transplantation</i> , 2018 , 24, 1655-1664	4.5	22
20	Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1639-1648	0.7	43
19	Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation. <i>Liver International</i> , 2017 , 37, 290-298	7.9	6
18	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 945-949.e1	6.9	18
17	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017 , 37, 1823-1832	7.9	8
16	Resistance to hepatitis C virus. Implications and therapeutic options. <i>Gastroenterology & Hepatology</i> , 2017 , 40, 484-494	0.9	1
15	Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA. <i>BMJ Open</i> , 2017 , 7, e013620	3	23
14	Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2017 , 109, 17-25	0.9	12
13	Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016 , 108, 421-30	0.9	2
12	Computerized Physician Order Entry-Based System Improves Hepatitis B Virus Screening in Patients Undergoing Chemotherapy. <i>Journal of Clinical Oncology</i> , 2016 , 34, 290	2.2	1
11	Biomarkers for monitoring alcohol use. <i>Clinical Liver Disease</i> , 2016 , 8, 59-63	2.2	21
10	Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. <i>Journal of Clinical Virology</i> , 2015 , 68, 56-60	14.5	9
9	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2015 , 35, 1775	7.9	
8	Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice. <i>Liver International</i> , 2015 , 35, 401-8	7.9	15
7	Plasma betatrophin levels in patients with liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10662-8	5.6	12

6	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015 , 14, 477-486	3.1	1
5	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015 , 62, 311-6	13.4	11
4	Binge drinking: Burden of liver disease and beyond. <i>World Journal of Hepatology</i> , 2015 , 7, 2703-15	3.4	36
3	Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. <i>Hepatology</i> , 2014 , 60, 106-13	11.2	21
2	AIDS-related gastric cryptosporidiosis simulating malignancy. <i>Revista Espanola De Patologia</i> , 2013 , 46, 247-251	1.2	0
1	Chemoprophylaxis with isoniazid in liver transplant recipients. <i>Liver Transplantation</i> , 2012 , 18, 1110-7	4.5	26